TITLE

Clinic Roundup

PUB. DATE
April 2013
SOURCE
BioWorld Today;4/11/2013, Vol. 24 Issue 69, p3
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article offers world news briefs in 2013. The U.S. approves BioLineRx Ltd. to commence its Phase IIa antagonist BL-8040 trial for acute myeloid leukemia (AML). It notes that Kwang Dong Pharmaceutical Co. Ltd. and Laboratorios Salvat SA has completed Phase IIb trial of Tarafenacin for overactive bladder syndrome treatment. Photocure ASA reports the final results from its Phase IIb research of Cevira in patients suffering from cervix disease associated to human papillomavirus (HPV).
ACCESSION #
87637996

 

Related Articles

  • Biolinerx shares hop on dual-action data in phase II AML trial. Boggs, Jennifer // BioWorld Today;12/17/2013, Vol. 24 Issue 241, p1 

    The article reports on the increased stock market performance of Biolinerx Ltd. posted on December 16, 2013. It also discusses the findings of the company's Phase II clinical drug trial for its CXCR4 antagonist, BL-8040, for treatment of patients with relapsed and refractory acute myeloid...

  • CLINIC ROUNDUP.  // BioWorld Today;1/14/2014, Vol. 25 Issue 9, p7 

    This section offers news briefs on clinical trials in the biotechnology industry as of January 14, 2014. Biolinerx Ltd. has announced the filing of the regulatory submissions to begin a Phase I study for the acute myeloid leukemia drug candidate BL-8040. Debiopharm Group has finished the...

  • MGI PHARMA/METHYLGENE BEGIN CLINICAL TRIAL OF MG98.  // Worldwide Biotech;Mar2002, Vol. 14 Issue 3, p8 

    Reports on the clinical trial initiated by MGI Pharma Inc. and MethylGene Inc. on MG98, a DNA methyltransferase inhibitor for patients with advanced myelodysplasia or acute myeloid leukemia.

  • Dr Frassoni’s paper was shown to Dr Sue Richards, who has commented as follows. Richards, S // Bone Marrow Transplantation;3/1/2000, Vol. 25 Issue 5, p472 

    Offers observation on a problem of applying the results of randomized trials to the individual patient with acute myelocytic leukemia (AML). Description on randomized trials; Reason for not receiving a transplant.

  • Randomised studies in acute myeloid leukaemia: the double truth. Frassoni, F // Bone Marrow Transplantation;3/1/2000, Vol. 25 Issue 5, p471 

    Comments on randomized studies in acute myeloid leukaemia (AML). Three major therapeutic options for AML; Major problems faced by reported studies; Main reason for publishing the results of clinical trials in major scientific journals.

  • Acute megakaryoblastic leukemia: experience of GIMEMA trials. Pagano, L.; Pulsoni, A.; Vignetti, M.; Mele, L.; Fianchi, L.; Petti, M.C.; Mirto, S.; Falcucci, P.; Fazi, P.; Broccia, G.; Specchia, G.; Di Raimondo, F.; Pacilli, L.; Leoni, P.; Ladogana, S.; Gallo, E.; Venditti, A.; Avanzi, G.; Camera, A. // Leukemia (08876924);Sep2002, Vol. 16 Issue 9, p1622 

    The objective of the study was to evaluate the incidence, characteristics, treatment and outcome of acute megakaryoblastic leukemia (AMeL) in patients enrolled in GIMEMA trials. Between 1982 and 1999, 3603 new consecutive cases of AML aged over 15 years were admitted to GIMEMA trials. Of them,...

  • Clinic Roundup.  // BioWorld Today;1/27/2011, Vol. 22 Issue 18, p5 

    This section offers news briefs on clinical trials, including ChemoCentryx Inc.'s Phase I trial of CCX832, an oral, small-molecule inhibitor of ChemR23 aimed at treating psoriasis, the Phase II results for Photocure ASA's photodynamic therapy Cevira, and positive results from Resverlogix Corp.'s...

  • Phase II success. Robinson, Kevin // Pharmaceutical Technology Europe;Oct2001, Vol. 13 Issue 10, p10 

    Reports on the success of Phase II clinical trials for Hexvix, a tool for the diagnosis of bladder cancer, developed by PhotoCure ASA. Significance of the outcome of the clinical trials for the company; Details of the clinical trials; Comparison between the results of Hexvix fluorescence...

  • Infectious complications in pediatric acute myeloid leukemia: analysis of the prospective multi-institutional clinical trial AML-BFM 93. Lehrnbecher, T.; Varwig, D.; Kaiser, J.; Reinhardt, D.; Klingebiel, T.; Creutzig, U. // Leukemia (08876924);Jan2004, Vol. 18 Issue 1, p72 

    Infections still remain a major cause of therapy-associated morbidity and mortality in children with acute myeloid leukemia (AML). To improve supportive care measurements, detailed information on frequency and characteristic features of infectious complications is needed. We retrospectively...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics